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Effects of Chloroquine and Sulfadoxine/Pyrimethamine on
Gametocytes in Patients with Uncomplicated Plasmodium
falciparum Malaria in Colombia
Lyda Osorio/*, Beatriz E Ferro/+, Carmen M Castillo
Centro Internacional de Entrenamiento e Investigaciones Médicas, Avenida 1 Norte No. 3-03, Cali, Colombia
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The effect of antimalarials on gametocytes can influence transmission and the spread of drug resistance. In order
to further understand this relationship, we determined the proportion of gametocyte carriers over time post-treat-
ment in patients with uncomplicated  Plasmodium falciparum malaria who were treated with either chloroquine (CQ)
or sulfadoxine/pyrimethamine (SP). The overall proportion of gametocyte carriers was high (85%) and not statis-
tically significantly different between the CQ and SP treatment groups. However, an increased risk of carrying
gametocytes on day 14 of follow up (1.26  95% CI 1.10-1.45) was found among patients having therapeutic failure
to CQ compared with patients having an adequate therapeutic response. This finding confirms and extends reports
of increased risk of gametocytaemia among CQ resistant P. falciparum.
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In spite of several in vivo and in vitro studies (Hogh
et al. 1998, Buckling et al. 1999, Robert et al. 2000), the
effect of chloroquine (CQ) and sulfadoxine/pyrimethamine
(SP) on gametocytes in patients with Plasmodium
falciparum malaria remains unclear. If after treatment a
considerable proportion of patients carry gametocytes this
would increase transmission. Likewise, if resistant para-
sites are more likely to develop gametocytes after treat-
ment, the spread of drug resistance would be favoured.
The present study examines the effect of these two
antimalarials on gametocytaemia and explores the influ-
ence of treatment failure on gametocyte carriage.
MATERIALS AND METHODS
In 1998, a 14-day in vivo randomized trial of the effi-
cacy of CQ and SP to treat uncomplicated P. falciparum
malaria in Quibdó, Colombia was conducted (Osorio et al.
1999). Thick blood film slides from 98 out of 141 patients
who had participated in this study were examined for the
presence and density of asexual and sexual parasites.
Asexual parasitaemia was measured by dividing the num-
ber of asexual parasites found in 300 leukocytes by 300
and multiplying by 8,000 (the estimated number of leuko-
cytes per microliter of blood). The presence of gameto-
cytes was evaluated in 1,000 leukocytes (approximately
200 fields), and gametocyte density was estimated by
counting the number of sexual forms in 1,000 leukocytes
and multiplying by 8. Two laboratory technicians with
expertise in malaria microscopy read all slides blinded.
Discordant results were evaluated by a qualified third
reader, who did not know the results of the previous read-
ers. EPINFO 6.04b (CDC 1997) was used for data analysis.
Data was compared using 2 x 2 tables. Continous vari-
ables were compared by Kruskal-Wallis test, and categori-
cal data by Chi-squared or Fisher’s exact test when re-
quired.
RESULTS
Forty-two patients received CQ and 56 SP. As in the
original study, in this subset CQ- and SP-treated groups
were similar in demographic and malaria characteristics at
enrollment but differed in the presence of CQ in urine and
treatment failure (Table). The overall proportion of pa-
tients with gametocytes at enrollment was 25.5% (25/98).
Most patients in the study developed gametocytes over
14 days of follow up, and the proportion of patients carry-
ing gametocytes in blood peaked on day 7 (85.7% in CQ-
treated and 86% in SP-treated patients) (Figure). Factors
such as age, parasite density at enrollment, duration of
symptoms (fever) and presence of CQ in urine were not
associated with gametocyte carriage at enrollment, nor at
follow up.
The geometric mean gametocyte density was compa-
rable between groups at enrollment (61 gametocytes/µl in
CQ-treated vs 73 gametocytes/µl in SP-treated patients)
and on all subsequent control days. Gametocyte density
also peaked on day 7 for both treatment groups, being
214.3 gametocytes/µl in CQ-treated and 276 gametocytes/
µl in SP-treated patients.
The influence of therapeutic failure on the presence
of gametocytes was assessed among CQ-treated patients.
It was found that the risk of having gametocytes on day
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14 was higher for those patients who presented therapeu-
tic failure than for those who respond to treatment RR =
1.26 (95% CI 1.10-1.45) (Figure). There were no differences
in gametocyte density between CQ therapeutic failure and
therapeutic response groups during the follow up (data
not shown).
DISCUSSION
In the present study a high proportion of patients (over-
all 85%) carried gametocytes after treatment with either
CQ or SP. Hence, the increased prevalence of gametocyte
carriers seen in SP-treated vs CQ-treated patients reported
by others was not detected (Robert et al. 2000, von Seidlein
et al. 2001). However, the higher risk of carrying gameto-
cytes in patients harboring CQ-resistant parasites was
confirmed (Robert et al. 1996).
The proportion of CQ-treated patients who developed
gametocytes was higher in our study than those reported
both in Senegal (hypoendemic area) (Robert et al. 2000)
and  Gambia (hyperendemic area) (von Seidlein et al. 2001).
The study conducted in Senegal and ours were compa-
rable with respect to the level of CQ resistance, age of
participants, duration of symptoms prior to diagnosis, and
method for detecting gametocytes. Therefore, other fac-
tors such as differences in the propensity of strains to
produce gametocytes (Buckling et al. 1999) or prevalence
of anaemia, which has been identified as an independent
risk factor for gametocyte carriage (Price et al. 1999), are
more likely to explain the difference in prevalence of ga-
metocyte carriers between studies. Haematocrit levels were
not measured in the present study.
In contrast to the 62.2% gametocyte carriers on day 7
of follow up found in Senegal and 85.7% in our study, in
Gambia only 18% of CQ-treated patients carried gameto-
cytes on day 7. The lower prevalence of gametocyte car-
riers could be explained in part by the lower level of CQ
resistance (30.2% vs 58% in Senegal and 43% in Quibdó,
Colombia) and the smaller number of thick-blood fields
examined in the Gambian study (100 fields instead of 200
fields). Measuring the effect of antimalarials on gameto-
cytes, in addition to their therapeutic efficacy, is becom-
ing more important due to the potential impact of gameto-
cyte development on the spread of drug resistance. There-
fore, methods to detect the presence of live gametocytes
as well as gametocyte density require standardization.
Although infectivity to mosquitoes seems to be lower
in SP-treated rather than CQ-treated patients, whether CQ
or SP enhances infectivity to mosquitoes is still contro-
versial (Hogh et al. 1998, Robert et al. 2000, Targett et al.
2001). There is more agreement on the selective advan-
tage of CQ-resistant over CQ-sensitive parasites in terms
of transmission, based on both prevalence of gametocyte
carriers and infectivity to mosquitoes (Hogh et al. 1998,
Robert et al. 2000). As in the present report, most studies
have found that the proportion of CQ-treated patients
harboring gametocytes is higher among those presenting
therapeutic failures than patients with adequate thera-
peutic response (Robert et al. 1996, 2000, von Seidlein et
CQR= Patients with therapeutic failure to CQ 
CQS= Patients with adequate therapeutic response to CQ 
SP/S= Patients with adequate therapeutic response to SP 
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Proportion of gametocyte carriers at enrollment and follow up per
treatment and therapeutic response. CQ: chloroquine; SP:
sulfadoxine/pyrimethamine
TABLE
Demographic and malaria characteristics at enrollment, and therapeutic response in patients treated with chloroquine (CQ) or
sulfadoxine/pyrimethamine (SP)
Characteristic CQ n = 42 (%) SP n = 56 (%)
Males 23  (55) 33  (59)
Mean of age (years) 23.3 19.7
1-14 15  (36) 23  (41)
15-44 24  (57) 28   (50)
45+  3  (7) 5  (9)
Mean (SD) of days of symptoms (fever) 6  (4.2) 5.8(5.2)
Presence of CQ in urine 11/28 (69) 5/32  (31)
Geometric mean of asexual parasitaemia/µl (range) 4,275 4,897
(1,000 - 35,399) (1,000 - 26,668)
Presence of gametocytes at enrollment 12  (29) 13  (23)
Therapeutic failure 18  (43) 3  (5)
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al. 2001). Nevertheless, the relative risk found in our study
(1.26 95% CI 1.10-1.45) was lower than that of other re-
ports (3.5 95% CI 1.67-7.34) (Robert et al. 2000). Although
further studies are needed, these findings suggest that
the transmission advantage of CQ resistant parasites, and
its impact on the spread of drug resistance, could vary
geographically due to differences in the proportion of
gametocyte carriage in patients harboring CQ-susceptible
parasites. If this is the case, it would in part explain the
lower speed with which CQ resistance has increased in
some regions.
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